AKT1 and COVID-19: Chloroquine/hydroxychloroquine acts as a TNFR antagonist and PI3K/AKT signaling inhibitor to suppress the NF-κB activation, while the severe COVID-19 patients didn’t benefit from chloroquine/ hydroxychloroquine [49].